South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
CLEVELAND, Feb. 14, 2017 -- Athersys, Inc. (Nasdaq:ATHX) will release its year-end 2016 financial results at approximately 4:00 PM Eastern Time on Thursday, March 9, 2017, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:
| Date | March 9, 2017 |
| Time | 4:30 p.m. (Eastern Time) |
| Telephone access: US and Canada | (800) 273-1254 |
| Telephone access: International | (973) 638-3440 |
| Access code | 73151585 |
| Live webcast | www.athersys.com under Investors section |
A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM Eastern Time on March 23, 2017 at the aforementioned URL, or by dialing (800) 585-8367 or (855) 859-2056 in the U.S. and Canada, or from abroad (404) 537-3406, and entering access code 73151585.
About Athersys
Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, cardiovascular, and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products. More information is available at www.athersys.com.
ATHX-G
Contact: William (B.J.) Lehmann, J.D. President and Chief Operating Officer Tel: (216) 431-9900 [email protected] David Schull Russo Partners, LLC 12 West 27th Street, 4th Floor New York, NY 10001 Tel: (212) 845-4271 [email protected]
